GC Cell's AB-101 NK therapy achieves FDA fast-track status
AB-101 is currently undergoing phase 1 and 2 clinical trials for patients with recurrent and intractable B-cell non-Hodgkin lymphoma
By Feb 02, 2023 (Gmt+09:00)
Macquarie Korea Asset Management confirms two nominees
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Korea's Taeyoung to sell local hotel to speed up debt workout
Meritz leaves door open for an M&A, to stay shareholder friendly
South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US Food and Drug Administration (FDA) for its natural killer (NK) cell therapy candidate AB-101.
AB-101 is a cord blood-derived treatment aimed at harnessing the body's immune system to fight cancer. GC Cell transferred the technology for this product to Artiva.
The treatment is currently undergoing phase 1 and 2 clinical trials for patients with recurrent and intractable B-cell non-Hodgkin lymphoma, including those who have failed to respond to chimeric antigen receptor T cell (CAR-T) treatment.
The FDA's fast-track designation is given to drugs that show potential for excellent efficacy against life-threatening diseases and are in need of quick development.
GC Cell, which was created through the merger of GC Green Cross Lab Cell and GC Green Cross Cell, is a corporation focused on the development and production of treatments using immune cells and stem cells.
Write to Jeong Min Nam at peux@hankyung.com
-
Bio & PharmaGC Biopharma's Sanfilippo treatment eligible for FDA priority review
Jan 18, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaGC Biopharma confirms safety of flu vaccine in phase 1 trial
Dec 15, 2022 (Gmt+09:00)
1 Min read